LEADS BIOLABS-B (09887): First Patient Successfully Dosed in Phase Ib/II Trial of LBL-024 for Melanoma Treatment

Stock News

09/12

LEADS BIOLABS-B (09887) announced that the first patient has been successfully dosed in a Phase Ib/II clinical trial (NCT07099430) evaluating opatasumib (LBL-024), a PD-L1/4-1BB bispecific antibody, as monotherapy or combination therapy for first-line treatment of advanced melanoma.

The Phase Ib/II multicenter clinical trial is led by Professor Chen Yu from Fujian Cancer Hospital, with participation from multiple hospitals nationwide. The study aims to evaluate the efficacy and safety of opatasumib as a single agent or in combination with other agents for treating advanced melanoma.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1188794473"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1188794473\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1188794473?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-12 12:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188794473","market":"fut","top_or_hot":-1,"title":"LEADS BIOLABS-B (09887): First Patient Successfully Dosed in Phase Ib/II Trial of LBL-024 for Melanoma Treatment","media":"Stock News","content":"<p>LEADS BIOLABS-B (09887) announced that the first patient has been successfully dosed in a Phase Ib/II clinical trial (NCT07099430) evaluating opatasumib (LBL-024), a PD-L1/4-1BB bispecific antibody, as monotherapy or combination therapy for first-line treatment of advanced melanoma.</p>\n<p>The Phase Ib/II multicenter clinical trial is led by Professor Chen Yu from Fujian Cancer Hospital, with participation from multiple hospitals nationwide. The study aims to evaluate the efficacy and safety of opatasumib as a single agent or in combination with other agents for treating advanced melanoma.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEADS BIOLABS-B (09887): First Patient Successfully Dosed in Phase Ib/II Trial of LBL-024 for Melanoma Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEADS BIOLABS-B (09887): First Patient Successfully Dosed in Phase Ib/II Trial of LBL-024 for Melanoma Treatment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-09-12 12:24</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>LEADS BIOLABS-B (09887) announced that the first patient has been successfully dosed in a Phase Ib/II clinical trial (NCT07099430) evaluating opatasumib (LBL-024), a PD-L1/4-1BB bispecific antibody, as monotherapy or combination therapy for first-line treatment of advanced melanoma.</p>\n<p>The Phase Ib/II multicenter clinical trial is led by Professor Chen Yu from Fujian Cancer Hospital, with participation from multiple hospitals nationwide. The study aims to evaluate the efficacy and safety of opatasumib as a single agent or in combination with other agents for treating advanced melanoma.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1188794473","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188794473","pubTimestamp":1757651064,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LEADS BIOLABS-B (09887) announced that the first patient has been successfully dosed in a Phase Ib/II clinical trial (NCT07099430) evaluating opatasumib (LBL-024), a PD-L1/4-1BB bispecific antibody,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","09887":"维立志博-B"},"translate_title":"LEADS BIOLABS-B（09887）：LBL-024治疗黑色素瘤的Ib/II期试验中首位成功给药的患者","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"LEADS BIOLABS-B (09887) announced that the first patient has been successfully dosed in a Phase Ib/II clinical trial (NCT07099430) evaluating opatasumib (LBL-024), a PD-L1/4-1BB bispecific antibody, as monotherapy or combination therapy for first-line treatment of advanced melanoma.\nThe Phase Ib/II multicenter clinical trial is led by Professor Chen Yu from Fujian Cancer Hospital, with participation from multiple hospitals nationwide. The study aims to evaluate the efficacy and safety of opatasumib as a single agent or in combination with other agents for treating advanced melanoma.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}